Literature DB >> 23607435

Association of human cytomegalovirus DNAaemia and specific granzyme B responses in lung transplant recipients.

L Weseslindtner1, H Kerschner, D Steinacher, M Kundi, P Jaksch, B Simon, L Hatos-Agyi, A Scheed, W Klepetko, E Puchhammer-Stöckl.   

Abstract

In lung transplant recipients (LTRs), human cytomegalovirus (HCMV) DNAaemia could be associated with HCMV disease and reduced allograft survival. In the present study we analysed whether or not HCMV-specific granzyme B (Grz-B) responses indicating CD8(+) T cell cytotoxicity exert an impact on HCMV DNAaemia and relate to specific interferon (IFN)-γ secretion. HCMV-specific Grz-B responses were quantitated by enzyme-linked immunosorbent assay (ELISA) in 70 samples from 39 HCMV seropositive LTRs who were prospectively investigated for HCMV DNA plasma levels and IFN-γ kinetics using a standardized CD8(+) T cell assay (QuantiFERON®-CMV assay). In all LTRs who were protected from HCMV DNAaemia by early and persistent IFN-γ responses, Grz-B responses were also detected. In LTRs who developed episodes of HCMV DNAaemia, the Grz-B responses which were detected prior to viral DNA detection differed significantly in patients who experienced episodes with high (exceeding 1000 copies/ml) and low plasma DNA levels (P = 0·0290, Fisher's exact test). Furthermore, the extent of Grz-B release prior to viral DNAaemia correlated statistically with the detected levels of IFN-γ (P < 0·0001, Spearman's rank test). Of note, simultaneous detection of Grz-B and IFN-γ secretion was associated significantly with protection from high HCMV DNA plasma levels during the subsequent follow-up (P = 0·0057, Fisher's exact test), and this association was stronger than for IFN-γ detection alone. We conclude that, in addition to IFN-γ responses, Grz-B secretion by CD8(+) T cells is essential to control HCMV replication and a simultaneous measurement of IFN-γ and Grz-B could contribute to the immune monitoring of LTRs.
© 2013 British Society for Immunology.

Entities:  

Keywords:  DNAaemia; HCMV; cytomegalovirus; granzyme B; lung transplant recipients

Mesh:

Substances:

Year:  2013        PMID: 23607435      PMCID: PMC3949631          DOI: 10.1111/cei.12123

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation.

Authors:  Kirsten M L Hertoghs; Perry D Moerland; Amber van Stijn; Ester B M Remmerswaal; Sila L Yong; Pablo J E J van de Berg; S Marieke van Ham; Frank Baas; Ineke J M ten Berge; René A W van Lier
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

2.  Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

Authors:  D Kumar; S Chernenko; G Moussa; I Cobos; O Manuel; J Preiksaitis; S Venkataraman; A Humar
Journal:  Am J Transplant       Date:  2009-05       Impact factor: 8.086

3.  Cytomegalovirus in solid organ transplant recipients.

Authors:  A Humar; D Snydman
Journal:  Am J Transplant       Date:  2009-12       Impact factor: 8.086

Review 4.  Pathways of memory CD8+ T-cell development.

Authors:  Oliver Bannard; Matthew Kraman; Douglas Fearon
Journal:  Eur J Immunol       Date:  2009-08       Impact factor: 5.532

5.  Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression.

Authors:  Adam R Hersperger; Jeffrey N Martin; Lucy Y Shin; Prameet M Sheth; Colin M Kovacs; Gabriela L Cosma; George Makedonas; Florencia Pereyra; Bruce D Walker; Rupert Kaul; Steven G Deeks; Michael R Betts
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

6.  QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity.

Authors:  Stefano Giulieri; Oriol Manuel
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

7.  Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation.

Authors:  G Gerna; D Lilleri; A Chiesa; P Zelini; M Furione; G Comolli; C Pellegrini; E Sarchi; C Migotto; M Regazzi Bonora; F Meloni; E Arbustini
Journal:  Am J Transplant       Date:  2011-08-09       Impact factor: 8.086

8.  Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.

Authors:  Luiz F Lisboa; Deepali Kumar; Leticia E Wilson; Atul Humar
Journal:  Transplantation       Date:  2012-01-27       Impact factor: 4.939

9.  CD161 expression on hepatitis C virus-specific CD8+ T cells suggests a distinct pathway of T cell differentiation.

Authors:  John W Northfield; Victoria Kasprowicz; Michaela Lucas; Nadine Kersting; Bertram Bengsch; Bertram Bengsh; Arthur Kim; Rodney E Phillips; Bruce D Walker; Robert Thimme; Georg Lauer; Paul Klenerman
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

10.  The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression.

Authors:  Pratip K Chattopadhyay; Michael R Betts; David A Price; Emma Gostick; Helen Horton; Mario Roederer; Stephen C De Rosa
Journal:  J Leukoc Biol       Date:  2008-10-10       Impact factor: 4.962

View more
  2 in total

1.  Immune Monitoring of Infectious Complications in Transplant Patients: an Important Step towards Improved Clinical Management.

Authors:  Rajiv Khanna
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

2.  Granzyme B mediated function of Parvovirus B19-specific CD4(+) T cells.

Authors:  Arun Kumar; Maria F Perdomo; Anu Kantele; Lea Hedman; Klaus Hedman; Rauli Franssila
Journal:  Clin Transl Immunology       Date:  2015-07-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.